Funding profile · At-home diagnostics

InnaMed

InnaMed raised its money almost entirely through two small dollar crowdfunding rounds, not through the institutional venture rounds its own later account describes. No Form D was ever filed for it. In March 2023 its assets and technology went to Fluxergy, and its SEC filings stopped.

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

Reading the filings

1. Both priced rounds are documented, and neither is large.The Republic round closed at exactly its $1,070,000 cap, and the Wefunder round closed at $1,281,106. Together that is $2,351,106 raised on the public record across five years, both as SAFEs with valuation caps, not priced equity.
2. The company’s later total does not reconcile with any filing.A 2024 interview with co-founder Eshwar Inapuri put total capital raised at $4.5 million from Y Combinator, DCVC and Blue 9 Capital. Blue 9 Capital’s own portfolio page confirms it invested in InnaMed, but no Form D appears anywhere on SEC EDGAR for InnaMed under its name or its CIK. If institutional money came in outside the two Reg CF SAFEs, no public filing records it.
3. Reg CF is the only fundraising mechanism on the public record.Companies that raise through a private placement exempt under Section 4(a)(2) with only accredited investors, or that raise entirely inside a Reg CF SAFE that institutional investors also bought into, can avoid filing a Form D. Either is possible here. What is not possible is confirming the $4.5 million figure from a public source.
4. Revenue growth appears to have stalled.The company told investors 2020 revenue reached about $1.4 million, up sixfold from the prior year. The next annual report on file, covering fiscal year 2021, shows revenue of $1,439,995, almost the same number. Read together, revenue likely plateaued around $1.4 million rather than continuing to climb between 2020 and 2021.
5. The company was young and getting younger in relative headcount.Employees grew from 7 at the report covering fiscal year 2019 to 14 at the report covering fiscal year 2021, roughly matching the founder’s account of growth from about 3 people in 2018 to 14 or 15 by 2021.
6. The filings stop cold in 2022.No Form C, C-AR, C-U, C/A or C-TR has been filed under InnaMed’s CIK since April 28, 2022, ten months before the Fluxergy deal was announced. A dormant filer that later sells its technology and lets its domain lapse is consistent with a company that quietly wound down rather than one that had an active fundraising or reporting life afterward.

Commercial signals

What to watch

• Whether a Form D or other SEC filing ever surfaces to substantiate the $4.5 million total the company has cited.
• Whether Fluxergy discloses commercial results from the licensed InnaMed biosensor technology.
• Whether the NASA and HHS grant amounts InnaMed cited appear in a public federal award database.

The InnaMed story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Synapsica Healthcare: Also in Diagnostics. A Bengaluru company that tried to write the spine report for the radiologist
• Correlia Biosystems: Also in Diagnostics. A UC Berkeley spinout that stopped waiting for proteins to drift toward an antibody and started pushing them there with an electric field
• Scanwell Health: Also in Diagnostics. A Los Angeles company that turned a phone camera into a urinalysis reader and sold the first over-the-counter urine testing app in the United States
• PreDxion Bio: Also in Diagnostics. A University of Michigan spinout that built a thirty minute cytokine test for the intensive care unit, turned it toward COVID-19 in April 2020, then turned again toward

Sources

1. Public recordSEC EDGAR filing history and Form C filings, InnaMed, Inc., CIK 0001773255SEC EDGAR · 2019 to 2022
2. Public recordopenFDA 510(k) and PMA database, applicant search “InnaMed”FDA · checked Sep 25, 2026
3. IndependentInnaMed on Wefunder, investor deal profile with funding history tableKingscrowd, Sweeny Kumar · Apr 26, 2021
4. IndependentBlue 9 Capital portfolio page listing InnaMedBlue 9 Capital · captured Feb 27, 2023
5. IndependentWharton Impact Venture Associates Research Blood-Testing StartupThe Wharton School · May 22, 2019
6. IndependentFluxergy Acquires InnaMed’s Blood Testing Tech to Support Metabolic Panel Development360Dx, Staff Reporter · Mar 3, 2023
7. IndependentFluxergy acquires HomeLab technology from InnaMedPathology in Practice · Mar 10, 2023
8. IndependentInnaMed Makes the Move into Pennovation LabPennovation Works, Univ. of Pennsylvania · Oct 26, 2021
9. InterviewEshwar Inapuri, Former CEO & Co-Founder of InnaMed, on Founding Diagnostics CompaniesLifeSci Beat, Medha Sharma · Jan 21, 2024
10. CompanyFluxergy Acquires Employees, Assets and Licenses Technology from InnaMed, IncPRWeb/PR Newswire · Mar 2, 2023
11. CompanyInnaMed (YC W17) campaign page, total raised on WefunderWefunder · accessed Sep 25, 2026
12. Public recordInternet Archive Wayback Machine CDX index for innamed.comInternet Archive · checked Sep 25, 2026

Compiled from SEC and other public records and published reports as of September 25, 2026. Form C notices report offerings under Regulation Crowdfunding; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in InnaMed. This page is not an offer to sell or a recommendation to buy any security.